Lithuania benzodiazepine policy and communication programme
National prescribing recommendations, communication programmes and mandatory e-prescribing to promote responsible benzodiazepine and Z-drug use.
- Years
- 2020–2021
- Country
- Lithuania
- Topic
- Low value carePatient safetySleep
- Asks people to
- Stop
- Strategy
- Policy paired
- Channel
- Clinical setting
- Audience
- CliniciansGeneral publicPrescribers, public
Evidence
Quasi-experimentalMixed
ITS 2018-2024: immediate drop in hypnotic benzodiazepine prevalence and DDDs sold, but no change in trend; long-term use kept rising.
Sponsor (who paid)
- Lithuanian health authorities Foreign government
Credits (who made it)
Not recorded yet.
Sources
- Impact of policy measures targeting benzodiazepines and Benzodiazepine-related drugs in Lithuania: interrupted time series analysis evaluation · 2026 · DOI 10.1007/s00228-025-03992-7 · PMID 41649577
Research notes
Created 2026-10-23 from the sleep campaign literature search (PubMed and web search; OpenAlex was unreachable), see docs/sleep-campaigns-literature.md. Findings are paraphrased from abstracts, not full texts; official URLs come from search results and were not opened.
Record cases/lt-benzodiazepine-programme.json, updated 2026-10-23· Link to this campaign